DrugPatentWatch concentrates deep knowledge on more than 6,400 small-molecule drugs and 2,300 generic ingredients from 1,700 branded and generic pharmaceutical companies and 700 suppliers, and more than 4,300 active and expired US patents and 74,000 international patents spanning 93 countries and regional patent offices.
Clinical Trials for: vorinostat
Vorinostat Plus FND in Relapsed or Refractory Mantle Cell Lymphoma
Status: Not yet recruiting Condition: Mantle Cell Lymphoma
High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors
Status: Recruiting Condition: Unspecified Adult Solid Tumor, Protocol Specific
A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL)
Status: Recruiting Condition: Follicular Lymphoma; Marginal Zone Lymphoma; Mantle Cell Lymphoma
Ph I Vorinostat in the Treatment of Advanced Staged Oropharyngeal Squamous Cell Carcinoma
Status: Recruiting Condition: Stage III Squamous Cell Carcinoma of the Oropharynx; Stage IV Squamous Cell Carcinoma of the Oropharynx
Study of Vorinostat (MK-0683) an HDAC Inhibitor, or Placebo in Combination With Bortezomib in Patients With Multiple Myeloma (MK-0683-088 AMN)
Status: Active, not recruiting Condition: Multiple Myeloma
Vorinostat in Combination With Vinorelbine in Patients With Advanced Cancer
Status: Terminated Condition: Malignant Solid Tumour
Vorinostat, Carboplatin and Gemcitabine Plus Vorinostat Maintenance in Women With Recurrent, Platinum-Sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
Status: Terminated Condition: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer
Vorinostat and Doxorubicin in Treating Patients With Metastatic or Locally Advanced Solid Tumors
Status: Active, not recruiting Condition: Unspecified Adult Solid Tumor, Protocol Specific
Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1))
Status: Completed Condition: Multiple Myeloma
Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma
Status: Recruiting Condition: Brain Cancer
Courtesy of ClinicalTrials.org
See more clinical trials for this drug
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||Type||RLD||Patent No.||Product||Substance||Delist_Flag||Patent Expiration||Patented / Exclusive Use|
|CAPSULE; ORAL||021991||Oct 6, 2006||RX||Yes||<disabled>||ORPHAN DRUG EXCLUSIVITY|
|CAPSULE; ORAL||021991||Oct 6, 2006||RX||Yes||8,067,472||<disabled>||TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WTIH CUTANEOUS T-CELL LYMPHOMA (CTCL)|
|CAPSULE; ORAL||021991||Oct 6, 2006||RX||Yes||7,399,787||<disabled>||TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WTIH CUTANEOUS T-CELL LYMPHOMA (CTCL)|
|CAPSULE; ORAL||021991||Oct 6, 2006||RX||Yes||7,456,219||Y||<disabled>|
|The preview shows a limited data set. Complete access is available with a Subscription|
Export unavailable in trial.
Subscribe for complete access.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright © 2002-2013 thinkBiotech LLC. ISSN: 2162-2639`abc